AI-Powered Drug Repurposing Advances: Using Artificial Intelligence to Find New Cancer Treatments
/in Artificial Intelligence/by MaxAI Strikes Again: FDA Cleared an AI That Outperformed Human Pathologists in Missed Cases
/in Artificial Intelligence/by MaxRepurposing Non-Cancer Drugs: A New Frontier in Personalized Oncology
/in Artificial Intelligence, Preclinical Research/by MaxGenomenon Unveils Groundbreaking Genomic Knowledgebase Powered by AI
/in Artificial Intelligence/by MaxAI designed cancer drug gets FDA approval for clinical trials
/in Artificial Intelligence, Not PCa related/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 3/2026 January 18, 2026
- A-CAR032: a STEAP2-Targeted Armored CAR-T Enters First-in-Human Trial for Advanced Prostate Cancer January 16, 2026
- SL-28 Phase 1/2 Trial: A Potential Breakthrough for Advanced Solid Tumors January 16, 2026
- UPDATE: SECuRE Trial Phase 2 Shows 67% PSA50 Response in Heavily Pre-Treated mCRPC January 16, 2026
